Azithromycin for acute lower respiratory tract infections

Malinee Laopaiboon; Ratana Panpanich; Kyaw Swa Mya

doi:10.1002/14651858.CD001954.pub4

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Respuestas clínicas Cochrane
Guías
Temas

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Figure 1

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 3

Funnel plot of comparison: 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, outcome: 1.1 Clinical failure.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 1 Clinical failure.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 2 Clinical failure by diagnosis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 3 Clinical failure by age group.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 4 Clinical failure by dose regimen of azithromycin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 5 Clinical failure by type of antibiotic in control group.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 6 Sensitivity analysis excluding one large trial.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 7 Sensitivity analysis excluding three trials with missing data > 10%.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 8 Sensitivity analysis with the condition of concealment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 9 Microbial eradication.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 Azithromycin versus amoxycillin or amoxycillin‐clavulanate, Outcome 10 Adverse events.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Azithromycin versus amoxycillin or amoxycillin‐clavulanate

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical failure Show forest plot	15	2496	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.64, 1.85]

2 Clinical failure by diagnosis Show forest plot	15		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only

2.1 Acute bronchitis	6	1296	Risk Ratio (M‐H, Random, 95% CI)	0.63 [0.45, 0.88]
2.2 Acute exacerbation of chronic bronchitis	9	808	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.46, 3.32]
2.3 Pneumonia	5	392	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.45, 1.94]
3 Clinical failure by age group Show forest plot	15		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only

3.1 Adult	12	2112	Risk Ratio (M‐H, Random, 95% CI)	1.15 [0.60, 2.20]
3.2 Paediatric	3	384	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.45, 1.94]
4 Clinical failure by dose regimen of azithromycin Show forest plot	12	2112	Risk Ratio (M‐H, Random, 95% CI)	1.15 [0.60, 2.20]

4.1 500 mg once daily x 3	8	1631	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.55, 2.83]
4.2 500 mg single dose followed by 250 mg on day 2 to 5	4	481	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.25, 3.62]
5 Clinical failure by type of antibiotic in control group Show forest plot	15	2496	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.64, 1.85]

5.1 Amoxycillin	2	291	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.16, 1.05]
5.2 Amoxyclav	13	2205	Risk Ratio (M‐H, Random, 95% CI)	1.28 [0.71, 2.30]
6 Sensitivity analysis excluding one large trial Show forest plot	14	1742	Risk Ratio (M‐H, Random, 95% CI)	1.20 [0.69, 2.09]

7 Sensitivity analysis excluding three trials with missing data > 10% Show forest plot	12	2250	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.62, 2.03]

8 Sensitivity analysis with the condition of concealment Show forest plot	15	2496	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.64, 1.85]

8.1 Adequately concealed studies	3	281	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.25, 1.21]
8.2 Inadequately or unclearly concealed studies	12	2215	Risk Ratio (M‐H, Random, 95% CI)	1.32 [0.70, 2.49]
9 Microbial eradication Show forest plot	12	961	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.87, 1.03]

10 Adverse events Show forest plot	12	2406	Risk Ratio (M‐H, Random, 95% CI)	0.76 [0.57, 1.00]

Comparison 1. Azithromycin versus amoxycillin or amoxycillin‐clavulanate

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet